CEO Markison informed investors at the JPMorgan Health Conference that the company remained on schedule with FDA timelines for two other promising tamper-resistant pain killer drugs. Nonetheless, the road to approvable action letters is littered with potholes….
Read More at BNET Pharma….
Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.